Cargando…

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Detalles Bibliográficos
Autores principales:	Bhatnagar, Bhavana, Kohlschmidt, Jessica, Orwick, Shelley J., Buelow, Daelynn R., Fobare, Sydney, Oakes, Christopher C., Kolitz, Jonathan E., Uy, Geoff, Stock, Wendy, Powell, Bayard L., Nicolet, Deedra, Hertlein, Erin K., Mrózek, Krzysztof, Blachly, James S., Eisfeld, Ann-Kathrin, Baker, Sharyn D., Byrd, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448419/ https://www.ncbi.nlm.nih.gov/pubmed/37603350 http://dx.doi.org/10.1182/bloodadvances.2023010482

Ejemplares similares

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Association of social deprivation with survival in younger adult patients with AML: an Alliance study
por: Rebechi, Melanie, et al.
Publicado: (2023)

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
por: Eisfeld, A-K, et al.
Publicado: (2017)

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
por: Mrózek, Krzysztof, et al.
Publicado: (2019)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement
por: Bill, Marius, et al.
Publicado: (2021)

A precision medicine classification for treatment of acute myeloid leukemia in older patients
por: Mims, Alice S., et al.
Publicado: (2021)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2017)

P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA
por: Yang, Xining, et al.
Publicado: (2023)

Controlled variable selection in Weibull mixture cure models for high‐dimensional data
por: Fu, Han, et al.
Publicado: (2022)

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML
por: Larkin, Karilyn T., et al.
Publicado: (2022)

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA
por: Walker, Christopher J., et al.
Publicado: (2018)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

MuCor: mutation aggregation and correlation
por: Kroll, Karl W., et al.
Publicado: (2016)

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2021)

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
por: Whitman, Susan P., et al.
Publicado: (2013)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
por: Ngankeu, Apollinaire, et al.
Publicado: (2017)

No evidence for microsatellite instability in acute myeloid leukemia
por: Walker, Christopher J., et al.
Publicado: (2017)

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
por: Niederwieser, Christian, et al.
Publicado: (2014)

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)
por: Blum, William, et al.
Publicado: (2016)

Mutation Analysis of the WT1 Gene in Myelodysplastic Syndromes
por: Hosoya, Noriko, et al.
Publicado: (1998)

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts
por: Gregory, Thomas, et al.
Publicado: (2020)

Towards an understanding of kidney diseases associated with WT1 mutations
por: Dong, Lihua, et al.
Publicado: (2015)

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Two Cases of Isolated Diffuse Mesangial Sclerosis with WT1 Mutations
por: Hahn, Hyewon, et al.
Publicado: (2006)

Gonadal Function in 15 Patients Associated with WT1 Gene Mutations
por: Maesaka, Akiko, et al.
Publicado: (2006)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
por: Drenberg, Christina D., et al.
Publicado: (2019)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
por: Mims, Alice, et al.
Publicado: (2023)

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation
por: Kaneko, Y, et al.
Publicado: (2015)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations
por: Wasilewska, Anna Maria, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_01sovkhfre0uma801mi093snh9